Login to Your Account



Financings Roundup

Aragon Moves Cancer Pipeline Forward with $42M Series C

By Marie Powers
Staff Writer

Tuesday, March 6, 2012
Privately held Aragon Pharmaceuticals Inc. landed $42 million in an oversubscribed Series C financing to advance its pipeline of therapies targeting hormone-driven cancers, including ARN-509, the company's lead compound for the treatment of castration-resistant prostate cancer (CRPC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription